Labcorp Earnings Forecast at $4.64 Per Share on $3.76 Billion in Revenue
Key Facts
Markets are awaiting Labcorp’s third-quarter 2026 results before the market opens on October 28, with estimates of $4.64 per share and $3.76 billion in revenue, according to data compiled by MarketBeat. The company scheduled the results announcement before trading began and invited investors to follow a webcast at 9:00 a.m. Eastern Time. These figures are analyst estimates ahead of the announcement, not the company’s actual results. The date follows second-quarter results that showed revenue and adjusted earnings increased from the same period a year earlier. The company is scheduled to host its results call on October 28 at 9:00 a.m. Eastern Time.
Third-quarter estimates put revenue at $3.76 billion, compared with $3.56 billion in the same quarter last year, while earnings per share are forecast at $4.64, versus $4.18. The comparison shows year-over-year increases in both measures, according to figures reported by MarketBeat. In the second quarter, Labcorp reported revenue of $3.73 billion, up 5.8% from $3.53 billion a year earlier. Adjusted earnings per share were $4.99 in the second quarter, compared with $4.35 in the year-earlier period, a 14.9% increase. The second-quarter results provide a recent point of comparison when the new figures are released.
Labcorp raised its fiscal 2026 guidance following its second-quarter results, setting company-wide revenue at between $14.710 billion and $14.827 billion and adjusted earnings per share at between $18.10 and $18.55. The guidance assumptions were based on exchange rates in effect on June 30, 2026. The company said its revenue guidance includes the estimated impact of expected capital allocation, including acquisitions, share repurchases and dividends. At its September Investor Day, Labcorp reaffirmed its annual guidance, which it had updated in July, and presented its long-term outlook through 2029. That outlook included compound annual revenue growth of between 5% and 8%, and adjusted earnings-per-share growth of between 8.5% and 11.5%.
The period ahead of the results announcement coincided with two acquisition agreements announced by the company in October. On October 15, Labcorp agreed with OPKO Health to buy selected assets of BioReference for $722 million in cash at closing, with additional potential payments of up to $150 million tied to 4Kscore test revenue. The company estimated BioReference’s business would generate about $250 million in revenue in the first year after the deal closes, based on its current post-closing expectations. On October 20, it announced an agreement to buy Myriad Genetics’ prenatal testing business for $210 million in cash, plus the value of inventory at closing. Labcorp expects the deal to add about $160 million in revenue in its first year and to be slightly accretive to adjusted earnings in that year; completion is still expected by early 2027, subject to regulatory approvals and customary closing conditions.
Ahead of the results announcement, Labcorp shares, listed under the ticker LH, closed at $331.17 on October 27. The company is scheduled to hold its third-quarter results call at 9:00 a.m. Eastern Time on October 28. In connection with the other deal, Myriad said it intends to discuss the sale of its prenatal testing business and related regulatory changes during its quarterly results call on November 4, 2026. These upcoming dates provide milestones for tracking details of Labcorp’s results and its announced acquisition plans. The available information did not include actual third-quarter results or any subsequent update to its 2026 guidance.